View More Recent Stories
-
Bausch Health Co. (BHC) Rejects Bondholders' Debt Proposals - WSJ
-
Wells Fargo Reiterates Overweight Rating on Bausch & Lomb Corp. (BLCO)
-
Evercore ISI Upgrades Bausch & Lomb Corp. (BLCO) to Outperform
-
TPG, Blackstone (BX) Team Up to Bid for Bausch + Lomb Corporation (BLCO) - FT
-
Bausch + Lomb Corporation (BLCO) Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
-
Bausch & Lomb Corp. (BLCO) PT Raised to $19 at Stifel
-
Bausch + Lomb Corporation stock gains on reports of private equity interest
-
Bausch + Lomb Corporation (BLCO) Shares +1.7% in Premarket, Jefferies says LBO Model sees a $25 takeout price
-
Jefferies on Bausch & Lomb Corp. (BLCO): 'takeout price of $25 would generate an IRR of 21% over a 5-year period'
-
Bausch + Lomb Corporation (BLCO) Working with Goldman to Explore Sale - FT (earlier)
-
Bausch & Lomb Corp. (BLCO) PT Raised to $16 at Stifel
-
Bausch + Lomb Corporation (BLCO) Reports In-Line Q2 EPS; raises guidance
-
Jefferies on Bausch Health Companies (BHC): 'Another Case of Irresponsible Journalism Wreaks Havoc in Shares'
-
Truist on Bausch Health Companies (BHC) Bankruptcy Rumors: 'we think a potential bankruptcy filing would place the separation on hold'
-
Bausch & Lomb Corp. (BLCO) PT Raised to $20 at RBC Capital

